People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Ikena Oncology, Inc. | — | Biotechnology | Series C | $117.6M | $449.1M | 2025 |
| Translate Bio, Inc. | — | Biotechnology | Series C | $98.5M | $1.9B | 2016 |
| Spero Therapeutics, Inc. | — | Biotechnology | Series C | $92.2M | $150.5M | 2017 |
| Intellia Therapeutics, Inc. | — | Biotechnology | Series C | $70.0M | $2.9B | 2015 |
| Antares Therapeutics, Inc. | — | Biotechnology | Series B | $70.0M | $149.7M | 2025 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2013 |
| RaNA Therapeutics, LLC | — | Biotechnology | Series C | $63.8M | $2.6B | 2015 |
| Arteaus Therapeutics, LLC | — | Biotechnology | Series B | $19.2M | $619.2M | 2011 |
| IFM Therapeutics, Inc. | — | Biotechnology | Series B | $17.1M | $680.3M | 2016 |
| Annovation BioPharma, Inc. | — | Pharmaceuticals | Series A | $10.4M | $247.8M | 2012 |
| CoStim Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.9M | 2013 |
| IFM Cinque, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| IFM Quattro, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| Korro Bio, Inc. | — | Biotechnology | Seed | $4.0M | $177.6M | 2019 |
| RaNA Therapeutics, Inc. | — | Biotechnology | Seed | $2.7M | $118.3M | 2011 |
| IFM Continua, Inc. | — | Biotechnology | Pre-Seed | $350K | $19.3M | 2019 |
Jean-Francois Formela at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jean-Francois Formela on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Shelley Chu | 5 | 10 |
| Gary Glick | 5 | 7 |
| John Leonard | 4 | 4 |
| Brian Gallagher | 2 | 11 |
| Adam Friedman | 2 | 6 |
| David Grayzel | 2 | 6 |
| Keith Flaherty | 2 | 5 |
| Owen Hughes | 2 | 4 |
| Marian Nakada | 2 | 4 |
| Otello Stampacchia | 2 | 4 |
| ANKIT MAHADEVIA | 2 | 4 |
| Nessan Bermingham | 2 | 3 |
| Jeffrey Albers | 2 | 3 |
| Brian Francois Gallagher | 2 | 2 |
| Andrew Fedder | 2 | 2 |
| Brian Piper | 2 | 2 |
| Carl Gordon | 1 | 24 |
| Kevin Bitterman | 1 | 15 |
| Scott Jackson | 1 | 13 |
| Luke Evnin | 1 | 12 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.